{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:33:16Z","timestamp":1787729596180,"version":"build-2784847793"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.beem.2019.101347","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T18:51:50Z","timestamp":1571683910000},"page":"101347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Disease monitoring of patients with pheochromocytoma or paraganglioma by biomarkers and imaging studies"],"prefix":"10.1016","volume":"34","author":[{"given":"Florentine","family":"Schreiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.beem.2019.101347_bib1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2019.101347_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/EJE-13-0529","article-title":"Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites","volume":"169","author":"van Duinen","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2019.101347_bib3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1677\/ERC-07-0074","article-title":"The diagnosis and management of malignant phaeochromocytoma and paraganglioma","volume":"14","author":"Chrisoulidou","year":"2007","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.beem.2019.101347_bib4","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"2\u201303","key":"10.1016\/j.beem.2019.101347_bib5","first-page":"137","article-title":"Perioperative management of endocrine active adrenal tumors","volume":"127","author":"Schreiner","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"10.1016\/j.beem.2019.101347_bib6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/s-0031-1299707","article-title":"Metastatic pheochromocytoma and paraganglioma: focus on therapeutics","volume":"44","author":"Plouin","year":"2012","journal-title":"Horm Metab Res"},{"issue":"3","key":"10.1016\/j.beem.2019.101347_bib7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2019.101347_bib8","doi-asserted-by":"crossref","first-page":"R135","DOI":"10.1530\/EJE-16-0189","article-title":"Management OF endocrine disease: recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis","volume":"175","author":"Amar","year":"2016","journal-title":"Eur J Endocrinol\/Eur Fed Endocrinol Soc"},{"issue":"4","key":"10.1016\/j.beem.2019.101347_bib9","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1210\/jc.2004-1398","article-title":"Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma","volume":"90","author":"Amar","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2019.101347_bib10","first-page":"1583","article-title":"Predictive factors for malignant pheochromocytoma: analysis of 136 patients","volume":"185","author":"Feng","year":"2011","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.beem.2019.101347_bib11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.surg.2008.02.007","article-title":"Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle\/apoptosis gene expression analysis","volume":"143","author":"Strong","year":"2008","journal-title":"Surgery"},{"issue":"34","key":"10.1016\/j.beem.2019.101347_bib12","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","article-title":"Genetic testing in pheochromocytoma or functional paraganglioma","volume":"23","author":"Amar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.beem.2019.101347_bib13","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1007\/s00268-010-0744-5","article-title":"Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?","volume":"34","author":"Agarwal","year":"2010","journal-title":"World J Surg"},{"key":"10.1016\/j.beem.2019.101347_bib14","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-19-0159","article-title":"Pheochromocytoma and paraganglioma: clinical feature based disease probability in relation to catecholamine biochemistry and reason for disease suspicion","author":"Geroula","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2019.101347_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-09-0384","article-title":"Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma","volume":"161","author":"Kopetschke","year":"2009","journal-title":"Eur J Endocrinol\/Eur Fed Endocrinol Soc"},{"issue":"5","key":"10.1016\/j.beem.2019.101347_bib16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/01.HYP.29.5.1133","article-title":"Tumor recurrence and hypertension persistence after successful pheochromocytoma operation","volume":"29","author":"Plouin","year":"1997","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.beem.2019.101347_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"19","key":"10.1016\/j.beem.2019.101347_bib18","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma","volume":"346","author":"Neumann","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.beem.2019.101347_bib19","first-page":"369","article-title":"Pheochromocytoma and paraganglioma: implications of germline mutation investigation for treatment, screening, and surveillance","volume":"63","author":"Gomez","year":"2019","journal-title":"Arch Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2019.101347_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060809","article-title":"Optimizing genetic workup in pheochromocytoma and paraganglioma by integrating diagnostic and research approaches","volume":"11","author":"Gieldon","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.beem.2019.101347_bib21","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2018-02411","article-title":"Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2019.101347_bib22","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"17","key":"10.1016\/j.beem.2019.101347_bib23","first-page":"5615","article-title":"Mutations in the SDHB gene are associated with extra-adrenal and\/or malignant phaeochromocytomas","volume":"63","author":"Gimenez-Roqueplo","year":"2003","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.beem.2019.101347_bib24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jmedgenet-2017-105127","article-title":"Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD","volume":"55","author":"Andrews","year":"2018","journal-title":"J\u00a0Med Genet"},{"issue":"5","key":"10.1016\/j.beem.2019.101347_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0032-1304594","article-title":"A\u00a0decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma","volume":"44","author":"Buffet","year":"2012","journal-title":"Horm Metab Res"},{"issue":"8","key":"10.1016\/j.beem.2019.101347_bib26","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1158\/0008-5472.CAN-08-4057","article-title":"Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out","volume":"69","author":"Neumann","year":"2009","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.beem.2019.101347_bib27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.beem.2019.101347_bib28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e318190d12e","article-title":"Observer variation in the application of the pheochromocytoma of the adrenal gland scaled score","volume":"33","author":"Wu","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.beem.2019.101347_bib29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.beem.2019.101347_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187398","article-title":"Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma","volume":"12","author":"Koh","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.beem.2019.101347_bib31","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","article-title":"Biochemical diagnosis of pheochromocytoma: which test is best?","volume":"287","author":"Lenders","year":"2002","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.beem.2019.101347_bib32","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1530\/EJE-09-0996","article-title":"Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma","volume":"162","author":"Grouzmann","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2019.101347_bib33","first-page":"344","article-title":"Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan","volume":"50","author":"Giovanella","year":"2006","journal-title":"Q\u00a0J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.beem.2019.101347_bib34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1373\/clinchem.2006.076489","article-title":"Is supine rest necessary before blood sampling for plasma metanephrines?","volume":"53","author":"Lenders","year":"2007","journal-title":"Clin Chem"},{"issue":"23","key":"10.1016\/j.beem.2019.101347_bib35","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMc1101502","article-title":"Drugs and pheochromocytoma-don't be fooled by every elevated metanephrine","volume":"364","author":"Neary","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.beem.2019.101347_bib36","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1210\/jc.2009-0303","article-title":"Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors","volume":"94","author":"de Jong","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2019.101347_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/eje.0.1470085","article-title":"The value of plasma markers for the clinical behaviour of phaeochromocytomas","volume":"147","author":"van der Harst","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2019.101347_bib38","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.beem.2019.101347_bib39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4158\/EP171914.RA","article-title":"The physiology behind diabetes mellitus in patients with pheochromocytoma: a review of the literature","volume":"23","author":"Mesmar","year":"2017","journal-title":"Endocr Pract"},{"issue":"2\u201303","key":"10.1016\/j.beem.2019.101347_bib40","first-page":"129","article-title":"Metabolic alterations in patients with pheochromocytoma","volume":"127","author":"Erlic","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"10.1016\/j.beem.2019.101347_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1479-828X.2005.00344.x","article-title":"Diabetes mellitus as the only manifestation of occult phaeochromocytoma prior to acute haemorrhage in pregnancy","volume":"45","author":"Tong","year":"2005","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"4","key":"10.1016\/j.beem.2019.101347_bib42","first-page":"276","article-title":"Occult extraadrenal pheochromocytoma treated as diabetes mellitus","volume":"314","author":"Yamashita","year":"1997","journal-title":"Am J Med Sci"},{"issue":"3","key":"10.1016\/j.beem.2019.101347_bib43","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cyto.2010.03.011","article-title":"Adiponectin - a possible factor in the pathogenesis of carbohydrate metabolism disturbances in patients with pheochromocytoma","volume":"50","author":"Elenkova","year":"2010","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.beem.2019.101347_bib44","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2169\/internalmedicine.9089-17","article-title":"Decreased serum adiponectin level during catecholamine crisis in an obese patient with pheochromocytoma","volume":"57","author":"Okauchi","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2019.101347_bib45","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM196404232701702","article-title":"Elevated plasma free fatty acid concentrations in patients with pheochromocytoma. Changes with therapy and correlations with the basal metabolic rate","volume":"270","author":"Engelman","year":"1964","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.beem.2019.101347_bib46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2265.1991.tb00284.x","article-title":"Metabolic effects of pharmacological adrenergic blockade in phaeochromocytoma","volume":"34","author":"Krentz","year":"1991","journal-title":"Clin Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2019.101347_bib47","doi-asserted-by":"crossref","first-page":"E2093","DOI":"10.1210\/jc.2012-2823","article-title":"Bone resorption is increased in pheochromocytoma patients and normalizes following adrenalectomy","volume":"97","author":"Veldhuis-Vlug","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2019.101347_bib48","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1210\/jc.2017-00169","article-title":"Lower bone mass and higher bone resorption in pheochromocytoma: importance of sympathetic activity on human bone","volume":"102","author":"Kim","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2019.101347_bib49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ando.2019.04.003","article-title":"Emerging molecular markers of metastatic pheochromocytomas and paragangliomas","volume":"80","author":"Goncalves","year":"2019","journal-title":"Ann Endocrinol"},{"issue":"17","key":"10.1016\/j.beem.2019.101347_bib50","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.7150\/thno.35458","article-title":"Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p\/TSC2\/mTOR axis in metastatic pheochromocytoma\/paraganglioma","volume":"9","author":"Calsina","year":"2019","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.beem.2019.101347_bib51","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","article-title":"Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated O-methylated catecholamine metabolites","volume":"64","author":"Eisenhofer","year":"2018","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.beem.2019.101347_bib52","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/s-0031-1301339","article-title":"Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma","volume":"44","author":"Amar","year":"2012","journal-title":"Horm Metab Res"},{"issue":"4","key":"10.1016\/j.beem.2019.101347_bib53","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/eci.12245","article-title":"Clinical utility of chromogranin A in SDHx-related paragangliomas","volume":"44","author":"Zuber","year":"2014","journal-title":"Eur J Clin Investig"},{"issue":"1","key":"10.1016\/j.beem.2019.101347_bib54","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12022-011-9188-1","article-title":"Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification","volume":"23","author":"Eisenhofer","year":"2012","journal-title":"Endocr Pathol"},{"issue":"6","key":"10.1016\/j.beem.2019.101347_bib55","first-page":"803","article-title":"[Role of magnetic resonance in the study of benign and malignant pheochromocytomas. Quantitative analysis of the intensity of the resonance signal]","volume":"85","author":"Maurea","year":"1993","journal-title":"Radiol Med"},{"issue":"4","key":"10.1016\/j.beem.2019.101347_bib56","first-page":"365","article-title":"Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison","volume":"40","author":"Maurea","year":"1996","journal-title":"Q\u00a0J Nucl Med"},{"issue":"7","key":"10.1016\/j.beem.2019.101347_bib57","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/MNM.0b013e328345a340","article-title":"Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma","volume":"32","author":"Rufini","year":"2011","journal-title":"Nucl Med Commun"},{"issue":"1","key":"10.1016\/j.beem.2019.101347_bib58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1530\/ERC-11-0243","article-title":"False-negative (1)(2)(3)I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease","volume":"19","author":"Fonte","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2019.101347_bib59","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2018-02355","article-title":"Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma","author":"Rao","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.beem.2019.101347_bib60","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1210\/jc.2009-1248","article-title":"Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma","volume":"94","author":"Timmers","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.beem.2019.101347_bib61","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","article-title":"Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma","volume":"25","author":"Timmers","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.beem.2019.101347_bib62","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/EJE-06-0712","article-title":"The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome","volume":"156","author":"Kaji","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.beem.2019.101347_bib63","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1210\/jc.2011-0333","article-title":"Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy","volume":"96","author":"King","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2019.101347_bib64","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00330-004-2412-3","article-title":"CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas)","volume":"15","author":"Sahdev","year":"2005","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.beem.2019.101347_bib65","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1148\/radiology.165.1.3628794","article-title":"Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131 MIBG scintigraphy","volume":"165","author":"Quint","year":"1987","journal-title":"Radiology"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19300983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19300983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:56:09Z","timestamp":1761497769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X19300983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1521690X19300983"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2019.101347","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease monitoring of patients with pheochromocytoma or paraganglioma by biomarkers and imaging studies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2019.101347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101347"}}